Amarin Corporation plc (AMRN) Stock

About Amarin Corporation plc

Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.

Amarin Corporation plc is headquartered in IE.

Amarin Corporation plc (AMRN) stock trades at $14.58 with a market capitalization of $301.45M. The stock is valued at a negative price-to-earnings (P/E) ratio of -9.00, reflecting a net loss over the last twelve months, price-to-book of 0.67, price-to-sales of 1.40. Over the past 52 weeks the stock has ranged between $12.96 and $20.90, and currently trades 30.2% below its 52-week high.

On profitability, Amarin Corporation plc generates a return on equity (ROE) of -7.34% (negative, reflecting a net loss), return on capital employed of -8.01%, an operating margin of -17.38%, a net profit margin of -15.64%.

Official website: www.amarincorp.com

Amarin Corporation plc by the numbers, 2016–2025

Between 2016 and 2025 Amarin Corporation plc reported revenue of $130.0M rising to $214.0M, a change of +64.6% across 10 years. Compounded, revenue has grown -19.0% a year over five years, -16.6% over three, -6.5% over the last twelve months. Net profit rose to $-39.0M.

Operating margin went from -50.5% in 2016 to -6.5% in 2025, a gain of 43.9 percentage points. The most recent net margin is -15.64%. On a trailing twelve-month basis to Mar '26, revenue is $215.0M and net profit $-34.0M.

Borrowings fell from $116.0M to $12.0M, cash on hand is $307.8M, cash from operations was $7.0M in the latest year, positive in 2 of the last 10.

Return on equity has averaged -10.5% over five years, and was -8.5% in the most recent year.

The share price itself has compounded at -29.5% a year over five years, -17.8% over three, -8.0% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Amarin Corporation plc (AMRN) — frequently asked questions